UK weighs carrier status policy in neonatal screening
This article was originally published in Clinica
The introduction of two neonatal screening programmes - sickle cell disorders (SCDs) and cystic fibrosis (CF) - in England has led the UK's Department to Health to launch an investigation into how carrier status should be handled in these and similar screening programmes, with potential implications for the choice of technologies used.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.